Lupin bags USFDA approval for Brivaracetam Tablets; stock zooms ~3.5%

21 Dec 2022 , 01:12 PM

Lupin Limited today announced that its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets have been approved by the United States Food and Drug Administration (USFDA).

The drug will be available in 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. It is a generic equivalent of Briviact Tablets of UCB Inc.

Lupin stated that it plans to manufacture the product in its Nagpur, India facility.

As per the data released by IQVIA MAT in September 2022, RLD Briviact had an estimated annual sale of USD 420 million in the US markets.

Currently, Lupin operates 15 manufacturing sites, and 7 research centers globally. It maintains an exceptional workforce of more than 20,000 talent heads globally. It has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

At around 1.53 PM, Lupin was trading 3.63% higher at Rs 750.20, against previous close of Rs 725.95 on NSE. The counter hit intraday high and low of Rs 757.80 and Rs 722.10 respectively.

For feedback and suggestions, write to us at [e-mail]